University of Connecticut

Northeastern University

Alexander M Zvonok

Alexandros Makriyannis

Michael Sotirios Malamas

Qian Liu

Shakiru O Alapafuja

Shrouq I Farah

Disclosed herein are compounds represented by Structural Formula I: or a pharmaceutically acceptable salt thereof. Values for the variables in Structural Formula I are described herein. The compounds can be used to modulate (e.g., inhibit) N-acylethanolamine hydrolyzing acid amidase (NAAA) and thereby treat a variety of diseases, disorders and conditions mediated by NAAA, such as a gastrointestinal motility disorder, irritable bowel syndrome, an inflammatory bowel disorder, neuroinflammation, nicotine addiction, cancer, opioid dependence, analgesia, chemotherapy-induced neuropathic pain and pain. Also disclosed herein are compositions and methods including compounds of Structural Formula I, or a pharmaceutically acceptable salt thereof.

N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and use thereof

One aspect of the invention is concerned with cannabimimetic heteroindane analogs having affinities and/or selectivities for a cannabinoid receptor. A further aspect of the invention is concerned with pharmaceutical preparations employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.

Heteroindanes: a new class of potent cannabimimetic ligands

Growing community of inventors

Revere, MA, United States of America

Alexander M Zvonok